Whole body [11C]-dihydrotetrabenazine imaging of baboons: Biodistribution and human radiation dosimetry estimates

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 4, 2008, Pages 790-797

  Murthy, Rajan ^a,b   Harris, Paul ^a   Simpson, Norman ^a   Van Heertum, Ronald ^a,b   Leibel, Rudolph ^a   Mann, J John ^a,b   Parsey, Ramin ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Dihydrotetrabenazine; Dosimetry; Pancreatic beta cell; Positron emission tomography; Vesicular monoamine transporter type 2

Indexed keywords

DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; UNCLASSIFIED DRUG; CARBON; DRUG DERIVATIVE; TETRABENAZINE;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN; DOSIMETRY; INTESTINE; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; STOMACH; TISSUE DISTRIBUTION; WHOLE BODY IMAGING; ANIMAL; ANIMAL MODEL; CALIBRATION; METHODOLOGY; PAPIO; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY RADIATION;

ANIMALS; CALIBRATION; CARBON RADIOISOTOPES; MALE; MODELS, ANIMAL; PAPIO; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; TETRABENAZINE; TISSUE DISTRIBUTION; WHOLE-BODY IRRADIATION;

EID: 40949132162     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0648-2     Document Type: Article

References (39)

1. Parsons S. Transport mechanisms in acetylcholine and monoamine storage. FASEB J 2000;14:2423-34.
2. De La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 2003;49:20-3.
3. Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003;160:47-55.
4. Riddle EL, Topham MK, Haycock JW, Hanson GR, Fleckenstein AE. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 2002;449:71-4.
5. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neuroscience 2002;22:8705-10.
6. Lehericy S, Brandel J, Hirsch EC, Anglade P, Villares J, Scherman D, et al. Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. Brain Res 1994;659:1-9.
7. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourne MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-212.
8. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 2001;49:110-6.
9. Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM, et al. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry. 2000;157:1619-28.
10. Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. J Mol Neurosci 1994;5:149-64.
11. Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 2003;51:1027-40.
12. Maffei A, Liu Z, Witkowski P, Moschella F, Del Pozzo G, Liu E, et al. Identification of tissue-restricted transcripts in human islets. Endocrinology 2004;145:4513-21.
13. 11C]DTBZ. Nucl Med Biol 2006;33:855-64.
14. 11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. Nucl Med Biol 1994;21:151-6.
15. Frey KA, Wieland DM, Kilbourn MR. Imaging of monoaminergic and cholinergic vesicular transporters in the brain. Adv Pharmacol 1998;42:269-72.
16. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borght TM, et al. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol 1996;40:885-92.
17. Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol 1962;4:275-306.
18. Ashcroft GM, MacDougall EJ, Barker P. A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia. J Ment Sci 1961;107:287-93.
19. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-3.
20. Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med 1995;36:2252-60.
21. 11C]DASB in baboons. Nucl Med Biol 2004;31:1097-102.
22. 11C] methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter. Appl Radiat Isotopes 1993;44:1487-9.
23. 11C]dihydrotetrabenazine (DTBZ). Nucl Med Biol 1997;24:197-9.
24. Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995;278:249-52.
25. 11C]NNC 756. Synapse 1999;32:93-109.
26. 11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency. Biol Psychiatry 2005;57:102-6.
27. 11C-WAY100,635 in humans. J Nucl Med 2005;46:614-9.
28. Michel C, Sibomana M, Bol A. Preserving Poisson characteristics of PET data with weighted OSEM reconstruction. IEEE Trans Med Imaging 1999;2:1323-9.
29. Michel C, Sibomana M, Bol A, Bernard X, Lonneux M, Defrise M, Comtat C, Kinahan PE, Townsend DW. Preserving Poisson characteristics of PET data with weighted OSEM reconstruction. IEEE Med Imag Conf Rec 1998. M6-61. (on CD-ROM).
30. Swindler DR, Wood CD. An atlas of primate gross anatomy: baboon, chimpanzee, and man. Seattle: University of Washington Press; 1973.
31. 11C]-harmine in baboons. Nuclear Medicine Communications 2007, 28:748-754. Erratum in Nuclear Medicine Communications 2007, 28:882.
32. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software of internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.
33. Roberts MS, McLean S, Millingen KS, Galloway HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29:703-8.
34. Mehvar R, Jamali F, Watson MW, Skelton D. Direct injection high-performance liquid chromatography of tetrabenazine and its metabolite in plasma of humans and rats. J Pharm Sci 1986;75:1006-9.
35. Mehvar R, Jamali F, Watson MW, Skelton D. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987;15:250-5.
36. Green EC. Anatomy of the rat. New York: Hafner Publishing Company; 1935.
37. Weihe E, Eiden LE. Chemical neuroanatomy of the vesicular amine transporters. FASEB J 2000;14:2435-49.
38. Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R, Weihe E. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion 1999;60:428-39.
39. Hunyady B, Palkovits M, Mezey E. Vesicular monoamine transporters in the rat stomach. J Physiol Paris 2000;94:123-30.